AIMS: Sitagliptin is a selective inhibitor of dipeptidyl peptidase-4 (DPP-4) used to treat type 2 diabetes. The present aim was to evaluate pharmacokinetic (PK), pharmacodynamic (PD) and safety characteristics of sitagliptin following single doses in healthy, young Japanese males. METHODS: In this alternating two-panel, randomized, controlled double-blind study, six healthy Japanese male subjects (aged 20-46 years) in each panel received single oral doses of 5-400mg sitagliptin and two received placebo. Plasma and urine drug concentrations were measured from 0-48h post dose and plasma DPP-4 inhibition from 0-24h post dose. The results were compared with historical data from young, healthy non-Japanese males. RESULTS:Plasma concentrations of sitagliptin increased approximately in proportion to dose; maximum concentrations occurred 2-6h post-dose. The mean apparent terminal half-life for plasma sitagliptin was 9-14h, with the half-life slightly decreasing as the dose increased. The mean dose fraction excreted unchanged in the urine was 0.73-1.00. Ingestion of a traditional Japanese breakfast prior to dosing had only a minor effect on PK parameters. After correction for dilution and competition effects during assay, doses of sitagliptin ≥50mg resulted in weighted average DPP-4 inhibition from 0-24h post-dose >94% (without correction, >78%). No clinically meaningful differences in PK and DPP-4 inhibition parameters were found between Japanese and non-Japanese subjects. Sitagliptin was generally well tolerated and there were no serious adverse experiences or episodes of hypoglycaemia. CONCLUSIONS: The PK and PD findings from this study are consistent with once daily dosing of sitagliptin in Japanese patients with type 2 diabetes.
RCT Entities:
AIMS: Sitagliptin is a selective inhibitor of dipeptidyl peptidase-4 (DPP-4) used to treat type 2 diabetes. The present aim was to evaluate pharmacokinetic (PK), pharmacodynamic (PD) and safety characteristics of sitagliptin following single doses in healthy, young Japanese males. METHODS: In this alternating two-panel, randomized, controlled double-blind study, six healthy Japanese male subjects (aged 20-46 years) in each panel received single oral doses of 5-400mg sitagliptin and two received placebo. Plasma and urine drug concentrations were measured from 0-48h post dose and plasma DPP-4 inhibition from 0-24h post dose. The results were compared with historical data from young, healthy non-Japanese males. RESULTS: Plasma concentrations of sitagliptin increased approximately in proportion to dose; maximum concentrations occurred 2-6h post-dose. The mean apparent terminal half-life for plasma sitagliptin was 9-14h, with the half-life slightly decreasing as the dose increased. The mean dose fraction excreted unchanged in the urine was 0.73-1.00. Ingestion of a traditional Japanese breakfast prior to dosing had only a minor effect on PK parameters. After correction for dilution and competition effects during assay, doses of sitagliptin ≥50mg resulted in weighted average DPP-4 inhibition from 0-24h post-dose >94% (without correction, >78%). No clinically meaningful differences in PK and DPP-4 inhibition parameters were found between Japanese and non-Japanese subjects. Sitagliptin was generally well tolerated and there were no serious adverse experiences or episodes of hypoglycaemia. CONCLUSIONS: The PK and PD findings from this study are consistent with once daily dosing of sitagliptin in Japanese patients with type 2 diabetes.
Authors: Wei Zeng; Donald G Musson; Alison L Fisher; Li Chen; Michael S Schwartz; Eric J Woolf; Amy Qiu Wang Journal: J Pharm Biomed Anal Date: 2007-11-17 Impact factor: 3.935
Authors: Gary A Herman; Arthur Bergman; Fang Liu; Cathy Stevens; Amy Q Wang; Wei Zeng; Li Chen; Karen Snyder; Deborah Hilliard; Michael Tanen; Wesley Tanaka; Alan G Meehan; Kenneth Lasseter; Stacy Dilzer; Robert Blum; John A Wagner Journal: J Clin Pharmacol Date: 2006-08 Impact factor: 3.126
Authors: Pablo Aschner; Mark S Kipnes; Jared K Lunceford; Matilde Sanchez; Carolyn Mickel; Debora E Williams-Herman Journal: Diabetes Care Date: 2006-12 Impact factor: 19.112
Authors: Tristan M Sissung; Caitlin E Baum; C Tyler Kirkland; Rui Gao; Erin R Gardner; William D Figg Journal: Mol Biotechnol Date: 2010-02 Impact factor: 2.695
Authors: M Alba; D Sheng; Y Guan; D Williams-Herman; P Larson; J R Sachs; N Thornberry; G Herman; K D Kaufman; B J Goldstein Journal: Curr Med Res Opin Date: 2009-10 Impact factor: 2.580
Authors: Arthur J Bergman; Catherine Stevens; YanYan Zhou; Bingming Yi; Martine Laethem; Marina De Smet; Karen Snyder; Deborah Hilliard; Wesley Tanaka; Wei Zeng; Michael Tanen; Amy Q Wang; Li Chen; Gregory Winchell; Michael J Davies; Steven Ramael; John A Wagner; Gary A Herman Journal: Clin Ther Date: 2006-01 Impact factor: 3.393
Authors: Nieves Vélez de Mendizábal; Robert M Strother; Sherif S Farag; Hal E Broxmeyer; Steven Messina-Graham; Shripad D Chitnis; Robert R Bies Journal: Clin Pharmacokinet Date: 2014-03 Impact factor: 6.447